- Home
- KRMD vs AVIR Comparison
KRMD vs AVIR Comparison
Compare KRMD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | AVIR |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.6M | 266.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRMD | AVIR |
|---|---|---|
| Price | $5.62 | $3.48 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | 182.5K | ★ 393.0K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | N/A |
| Revenue This Year | $23.36 | N/A |
| Revenue Next Year | $18.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.12 | N/A |
| 52 Week Low | $1.86 | $2.46 |
| 52 Week High | $6.61 | $4.02 |
Technical Indicators
Market Signals| Indicator | KRMD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 58.89 |
| Support Level | $5.31 | $3.29 |
| Resistance Level | $6.61 | $3.63 |
| Average True Range (ATR) | 0.36 | 0.14 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 27.73 | 63.41 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).